Orly Leiva: Rethinking JAK Inhibitor Cardiovascular Safety in MPNs
Orly Leiva, Cardio-Oncology and Pulmonary Hypertension Cardiologist, Assistant Professor at University of Kentucky College of Medicine, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in JACC: CardioOncology, adding:
“Excited to share out new publication on the impact of JAK Inhibitors on cardiovascular outcomes in hematologic malignancies, particularly MPNs!
In this JACC Cardio-Oncology primer, we looked at the literature on cardiovascular risk with JAK inhibitors.
On the basis of the ORAL Surveillance trial, which demonstrated increased cardiovascular risk in rheumatoid arthritis with JAK Inhibitor vs TNF inhibitors, the FDA has placed a black box warning on all JAK inhibitors.
However, recent data from our group and others suggest that the impact of JAK inhibition is more nuanced.
Among patients with MPNs, for which JAK inhibitors are sometimes indicated in, suggest that there may be a reduced risk of thrombosis and HF events with JAK inhibition.
The discordance between the literature in RA and other autoimmune diseases and MPNs may be due to underlying disease pathophysiology, specific JAK-STAT types targeted and patient population.
More work needs to be done!
Thanks to Gabriela Hobbs, Michelle Bloom, Angie Seo for their help in this paper and for Michael Garshick for the invitation to help write this important work.
Always fun to mentor NYU Grossman School of Medicine medical students and University of Kentucky College of Medicine cardiology fellows in writing this as well!”
Title: Cardiovascular Considerations of JAK Inhibitors in Patients With Hematologic Malignancies: JACC CardioOncology Primer
Authors: Orly Leiva, Monica Ferrante, Sydney Lupo, Angie E. Seo, Gabriela Hobbs, Michelle Bloom, Michael Garshick
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 9, 2026, 17:11Ken Kuang: Why Your Calves Are Called Your “Second Heart”?
-
Nov 9, 2026, 17:07Mert Dumantepe: Key Insights From The 8th Abu Dhabi International Vascular Conference
-
Nov 9, 2026, 16:57Amrita Sarkar: Exciting Advances in Hematology and Vascular Research at 54th Annual Philadelphia Workshop
-
Nov 9, 2026, 16:47Joey Boxer Samuels: Prolonged Sitting and Vein Thrombosis
-
Nov 9, 2026, 13:48PF4-ELISA–Negative HIT: Are We Missing a New Class of Anti-PF4 Immunothrombotic Disease?
-
Nov 9, 2026, 13:07Nandini Sadasivam: Gene Therapy for Sickle Cell Disease and Thalassaemia
-
Nov 9, 2026, 13:04Raising Awareness of Bleeding Disorders in Women and Girls – EHC
-
Nov 9, 2026, 12:59Rahul Bohra: Exploring the Complex Mechanisms of Sickle Cell Disease
-
Nov 9, 2026, 12:53Three Years of Movement and Thrombosis Awareness in the Czech Republic – World Thrombosis day